Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma
Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of N...
Gespeichert in:
Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2013-08, Vol.86 (5), p.930-935 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 935 |
---|---|
container_issue | 5 |
container_start_page | 930 |
container_title | International journal of radiation oncology, biology, physics |
container_volume | 86 |
creator | Fasola, Carolina E., MD, MPH Jones, Jennifer C., MD, PhD Huang, Derek D., MD Le, Quynh-Thu, MD Hoppe, Richard T., MD Donaldson, Sarah S., MD |
description | Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse. |
doi_str_mv | 10.1016/j.ijrobp.2013.04.035 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301613004641</els_id><sourcerecordid>1399934306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</originalsourceid><addsrcrecordid>eNqFUsuO1DAQjBCIHRb-ACFLXJZDhvYjcXJBQgssiJFWgkHiZjl2h3hI4mBnFs2X8EH8GI5mWR6XPfng6qquqs6yxxTWFGj5fLd2u-Cbac2A8jWINfDiTrailaxzXhSf72Yr4CXkPIFPsgcx7gCAUinuZyeMS1YCsFX2fuO_5698RPJBW6dn50ey7TDo6UDOGLk4kJ8_CHtG3EjmDsk2oJ4HHGfiW3IZGjfrnmwOw9T5QT_M7rW6j_jo-j3NPr15vT1_m28uL96dv9zkphTFnEsm2ra0TLOCNrSpmLSNBImQdrIVLYygsqokNZqaFiyXgtemKipsSgvWNvw0e3HknfbNgNakdYLu1RTcoMNBee3Uvz-j69QXf6VkUUItykTw9Ejg4-xUNG5G0xk_jmhmxRgrZcWrhDq7lgn-2x7jrAYXDfa9HtHvo6KJjTIBIG6H8rquueCwaIsj1AQfY8D2Zm8KailW7dSxWLUUq0CoVGwae_K355uh303-CQVT8lcOw-ILR4PWhcWW9e42hf8JTO9GZ3T_FQ8Yd34fxtSqoioyBerjclzLbVGeEigF5b8A-5HJBg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399934306</pqid></control><display><type>article</type><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</creator><creatorcontrib>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</creatorcontrib><description>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</description><identifier>ISSN: 0360-3016</identifier><identifier>ISSN: 1879-355X</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2013.04.035</identifier><identifier>PMID: 23726002</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; EDEMA ; Female ; Follow-Up Studies ; Hematology, Oncology and Palliative Medicine ; Humans ; Lymphoma - radiotherapy ; Lymphoma, Non-Hodgkin - radiotherapy ; LYMPHOMAS ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Orbital Neoplasms - radiotherapy ; PATIENTS ; RADIATION DOSES ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Remission Induction ; REVIEWS ; SIDE EFFECTS ; TOXICITY</subject><ispartof>International journal of radiation oncology, biology, physics, 2013-08, Vol.86 (5), p.930-935</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</citedby><cites>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2013.04.035$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23726002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22267838$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Fasola, Carolina E., MD, MPH</creatorcontrib><creatorcontrib>Jones, Jennifer C., MD, PhD</creatorcontrib><creatorcontrib>Huang, Derek D., MD</creatorcontrib><creatorcontrib>Le, Quynh-Thu, MD</creatorcontrib><creatorcontrib>Hoppe, Richard T., MD</creatorcontrib><creatorcontrib>Donaldson, Sarah S., MD</creatorcontrib><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>EDEMA</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lymphoma - radiotherapy</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>LYMPHOMAS</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Orbital Neoplasms - radiotherapy</subject><subject>PATIENTS</subject><subject>RADIATION DOSES</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>Remission Induction</subject><subject>REVIEWS</subject><subject>SIDE EFFECTS</subject><subject>TOXICITY</subject><issn>0360-3016</issn><issn>1879-355X</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQjBCIHRb-ACFLXJZDhvYjcXJBQgssiJFWgkHiZjl2h3hI4mBnFs2X8EH8GI5mWR6XPfng6qquqs6yxxTWFGj5fLd2u-Cbac2A8jWINfDiTrailaxzXhSf72Yr4CXkPIFPsgcx7gCAUinuZyeMS1YCsFX2fuO_5698RPJBW6dn50ey7TDo6UDOGLk4kJ8_CHtG3EjmDsk2oJ4HHGfiW3IZGjfrnmwOw9T5QT_M7rW6j_jo-j3NPr15vT1_m28uL96dv9zkphTFnEsm2ra0TLOCNrSpmLSNBImQdrIVLYygsqokNZqaFiyXgtemKipsSgvWNvw0e3HknfbNgNakdYLu1RTcoMNBee3Uvz-j69QXf6VkUUItykTw9Ejg4-xUNG5G0xk_jmhmxRgrZcWrhDq7lgn-2x7jrAYXDfa9HtHvo6KJjTIBIG6H8rquueCwaIsj1AQfY8D2Zm8KailW7dSxWLUUq0CoVGwae_K355uh303-CQVT8lcOw-ILR4PWhcWW9e42hf8JTO9GZ3T_FQ8Yd34fxtSqoioyBerjclzLbVGeEigF5b8A-5HJBg</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Fasola, Carolina E., MD, MPH</creator><creator>Jones, Jennifer C., MD, PhD</creator><creator>Huang, Derek D., MD</creator><creator>Le, Quynh-Thu, MD</creator><creator>Hoppe, Richard T., MD</creator><creator>Donaldson, Sarah S., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope><scope>5PM</scope></search><sort><creationdate>20130801</creationdate><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><author>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>EDEMA</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lymphoma - radiotherapy</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>LYMPHOMAS</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Orbital Neoplasms - radiotherapy</topic><topic>PATIENTS</topic><topic>RADIATION DOSES</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>Remission Induction</topic><topic>REVIEWS</topic><topic>SIDE EFFECTS</topic><topic>TOXICITY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fasola, Carolina E., MD, MPH</creatorcontrib><creatorcontrib>Jones, Jennifer C., MD, PhD</creatorcontrib><creatorcontrib>Huang, Derek D., MD</creatorcontrib><creatorcontrib>Le, Quynh-Thu, MD</creatorcontrib><creatorcontrib>Hoppe, Richard T., MD</creatorcontrib><creatorcontrib>Donaldson, Sarah S., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fasola, Carolina E., MD, MPH</au><au>Jones, Jennifer C., MD, PhD</au><au>Huang, Derek D., MD</au><au>Le, Quynh-Thu, MD</au><au>Hoppe, Richard T., MD</au><au>Donaldson, Sarah S., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>86</volume><issue>5</issue><spage>930</spage><epage>935</epage><pages>930-935</pages><issn>0360-3016</issn><issn>1879-355X</issn><eissn>1879-355X</eissn><abstract>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23726002</pmid><doi>10.1016/j.ijrobp.2013.04.035</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3016 |
ispartof | International journal of radiation oncology, biology, physics, 2013-08, Vol.86 (5), p.930-935 |
issn | 0360-3016 1879-355X 1879-355X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560946 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Aged Aged, 80 and over EDEMA Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Lymphoma - radiotherapy Lymphoma, Non-Hodgkin - radiotherapy LYMPHOMAS Male Middle Aged Neoplasm Recurrence, Local Orbital Neoplasms - radiotherapy PATIENTS RADIATION DOSES Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy Dosage Remission Induction REVIEWS SIDE EFFECTS TOXICITY |
title | Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A33%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-Dose%20Radiation%20Therapy%20(2%20Gy%20%C3%97%202)%20in%20the%20Treatment%20of%20Orbital%20Lymphoma&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Fasola,%20Carolina%20E.,%20MD,%20MPH&rft.date=2013-08-01&rft.volume=86&rft.issue=5&rft.spage=930&rft.epage=935&rft.pages=930-935&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2013.04.035&rft_dat=%3Cproquest_pubme%3E1399934306%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1399934306&rft_id=info:pmid/23726002&rft_els_id=1_s2_0_S0360301613004641&rfr_iscdi=true |